Floatz logo

ERYTHROPOIETIN

Disease Related To Hematopoietic Stem Cell Transplant

Peking Universityprotein_peptidePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

55 Active assets in the Disease Related To Hematopoietic Stem Cell Transplant cohort.

Asset / SponsorPhaseRating
BUSULFANUM
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
Cyclophosphamide
The First Affiliated Hospital of Soochow University
Phase 3BBB
Nivestim
National Cancer Institute (NCI)
Phase 2/3BBB
Rituximab
M.D. Anderson Cancer Center
Phase 2BBB
Decitabine
Chinese PLA General Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

ERYTHROPOIETIN is also rated in:

anemiaDormant
BBB
Indicative · Phase 4
78 / 100
View asset →
stroke disorderDormant
BB
Indicative · Phase 2
64 / 100
View asset →
liver failureDormant
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →